TAMPA, Florida, Sept. 24, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform and Multi-Target Directed Bispecific Drug Conjugate platform, announced today that it sold the rights to GTB-004 for the treatment of myasthenia gra

NESS ZIONA, Israel, Sept. 24, 2019 /PRNewswire/ -- Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, today announced promising interim results of cohort A of its Phase 1/2a clinical trial for the treatment of patients with Amyotrophic Lat

OLDWICK, N.J., Sept. 24, 2019 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its regulatory strategy regarding PRV-031 (teplizumab) for the prevention or delay of clinical type 1 diabetes (T1D) in individuals at-risk of developin

KERALA, India, Sept. 24, 2019 /PRNewswire/ -- BCM-95® (Bio-curcumin®) a high-potency turmeric extract of curcumin manufactured and marketed by Arjuna Natural Pvt Ltd. is now backed by 60 scientific studies. With superior bioactivity and proven efficacy reinforced by clinical su

CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and its development and commercialization partner, Chie

TORRANCE, Calif., Sept. 24, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease (SCD) treatment, today released the following summary review of the clinical trials and efficacy findings for Endari®. "In light of our decision to withdraw our marketing authorization application (MAA) to the European Medicines

SAN CARLOS, Calif., Sept. 24, 2019 /PRNewswire/ -- Apexigen, Inc. today announced its participation at the following upcoming oncology-focused conferences to discuss the role of the CD40 pathway in next-generation cancer immunotherapy and Apexigen's lead product candidate APX005M, a monoclonal antibody targeting CD40. APX005M is currently in multiple ongoing clinica

DALLAS and NASHVILLE, Tenn., Sept. 24, 2019 /PRNewswire/ -- Pharos Capital Group, LLC ("Pharos"), through its Family Treatment Network platform ("FTN"), has completed an investment in Alpine Academy and Interventions Unlimited, which together provide Applied Behavior Analysis (ABA)-based educational services and ABA therapy to childr

SAN ANTONIO, Sept. 24, 2019 /PRNewswire/ -- Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesavin

ST. LOUIS, Sept. 24, 2019 /PRNewswire/ -- Centene Corporation (NYSE: CNC) and The National Foster Parent Association (NFPA) announced today a partnership to bring online trainings to foster caregivers nationwide via the NFPA's online Training Institute. Centene will provide the online platform and facilitators, and the NFPA will provide the educational mat